June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Anti-Transgene Cellular Immune Reponses can be Induced by Subretinal Gene Transfer with rAAV in a Dose-Dependent Manner
Author Affiliations & Notes
  • Sylvain Fisson
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Julie Vendomele
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Quentin Khebizi
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Safa Dehmani
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Mirella Mormin
    INSERM UMRS951, Genethon, Evry, France
  • Sabrina Donnou-Triffault
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Anne Galy
    INSERM UMRS951, Genethon, Evry, France
    University of Evry Val d'Essonne, Evry, France
  • Footnotes
    Commercial Relationships   Sylvain Fisson, None; Julie Vendomele, None; Quentin Khebizi, None; Safa Dehmani, None; Mirella Mormin, None; Sabrina Donnou-Triffault, None; Anne Galy, None
  • Footnotes
    Support  French Academic ATIGE grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5747. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sylvain Fisson, Julie Vendomele, Quentin Khebizi, Safa Dehmani, Mirella Mormin, Sabrina Donnou-Triffault, Anne Galy; Anti-Transgene Cellular Immune Reponses can be Induced by Subretinal Gene Transfer with rAAV in a Dose-Dependent Manner. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5747.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : From animal experiments to the first human clinical trials in 2007, recombinant adeno-associated virus (rAAV)-mediated ocular gene therapy has shown successful results which have been attributed in part to the immune-privileged situation of the eye. Recently, some ocular gene therapy clinical trials have reported that visual acuity returned to baseline 6 to 12 months after therapy. The involvement of anti-transgene immune responses may lead to loss of therapeutic efficacy. This prompted us to evaluate in a murine model if rAAV gene transfer leads to an anti-transgene immunization. In this study, we characterized the CD4 and CD8 T-cell responses specifically directed toward the transgene product in a murine model following rAAV2/8-mediated subretinal gene transfer.

Methods : A rAAV2/8 encoding for the GFP-HY fusion protein under the ubiquitous PGK promoter was used. The transgene expresses the HY male antigen which contains MHC class I and MHC class II-restricted T cell epitopes (UTY and DBY, respectively), that are immuno-dominant in female mice. Two µL of endotoxin-free, PBS-formulated rAAV2/8 PGK GFP-HY were injected subretinally in C57Bl/6 female mice. At day 7, mice were challenged subcutaneously with the UTY and DBY peptides adjuvanted in CFA, and the immune response was analyzed at day 14 by IFNg ELISpot, cytokine titration and proliferation assays.

Results : Our results revealed that: (i) The subretinal injection of 10E8 to 2.10E9 vg/mouse of rAAV2/8 PGK GFP-HY did not induce a significant HY-specific peripheral immune modulation in contrast to the ACAID obtained after subretinal injection of HY peptides (50µg each); (ii) Higher doses of rAAV2/8 PGK GFP-HY (5.10E10 vg/mouse) triggered increased Th1 and Tc1 cellular immune responses against the transgene product in peripheral lymphoid organs.

Conclusions : We show that rAAV2/8 vector-mediated subretinal gene transfer is not necessarily ignored at the immunological level. High doses of vector can effectively trigger anti-transgene T-cell responses with the potential for elimination of transgene-expressing cells. Clearly, anti-transgene-specific immune monitoring should be refined at least in preclinical models, to improve the biosafety and the long-term efficacy of rAAV-mediated ocular gene transfer. Moreover, immunosuppressive strategies concomitant to the AAV injection are currently being tested.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×